Published in Hepatitis Weekly, June 14th, 2004
More than 20 leading transplant centers in the U.S., Canada, and Europe, including Emory University, participated in a phase II study comparing LEA29Y, also known as BMS-224818, to a similar regimen containing standard therapy with cyclosporine.
Study results showed that 6 months following kidney transplant, LEA29Y was as effective as standard therapy with cyclosporine in preventing acute rejection. However, LEA29Y-treated patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.